Fujisawa Inc, released data recently that supports the safety and efficacy of Protopic (tacrolimus ointment) 0.03 percent concentration in children with mild to moderate atopic dermatitis.
Skin Swab Analysis Reveals Early Predictors of Atopic Dermatitis in Infants
The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
Lisa Swanson, MD, FAAD: Clinical Pearls and Updates for Pediatric Dermatology
The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma
Lawrence Eichenfield, MD: Outlining Late-Breaking INTEGUMENT-PED Data for Roflumilast in Pediatric Patients
Evolution and Innovation in Treating Psoriasis in Pediatric Patients